The University of Southampton
University of Southampton Institutional Repository

The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study

The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study
The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study

Objectives: midregional pro-adrenomedullin (MR-proADM) is a vasoactive peptide with key roles in reducing vascular hyperpermeability and thereby improving endothelial stability during infection. While MR-proADM is useful for risk stratification in patients with sepsis, clinical data about prediction accuracy in patients with severe acute respiratory syndrome coronavirus 2 disease (COVID-19) is currently missing.

Methods: we included consecutively adult patients hospitalized for confirmed COVID-19 at a tertiary care center in Switzerland between February and April 2020. We investigated the association of MR-proADM levels with in-hospital mortality in logistic regression and discrimination analyses.

Results: of 89 included COVID-19 patients, 19% (n=17) died while in the hospital. Median admission MR-proADM levels (nmol/L) were increased almost 1.5-fold increased in non-survivors compared to survivors (1.3 [interquartile range IQR 1.1-2.3]) vs. 0.8 [IQR 0.7-1.1]) and showed good discrimination (area under the curve 0.78). An increase of 1 nmol/L of admission MR-proADM was independently associated with a more than fivefold increase in in-hospital mortality (adjusted odds ratio of 5.5, 95% confidence interval 1.4-21.4, p=0.015). An admission MR-proADM threshold of 0.93 nmol/L showed the best prognostic accuracy for in-hospital mortality with a sensitivity of 93%, a specificity of 60% and a negative predictive value of 97%. Kinetics of follow-up MR-proADM provided further prognostic information for in-hospital treatment.

Conclusions: increased levels of MR-proADM on admission and during hospital stay were independently associated with in-hospital mortality and may allow a better risk stratification, and particularly rule-out of fatal outcome, in COVID-19 patients.

biomarker, COVID-19, in-hospital mortality, prognostic markers, SARS-CoV-2
1434-6621
995-1004
Gregoriano, Claudia
bf93f5bd-6dff-4906-8b2f-8751d03bb237
Koch, Daniel
476659ae-269d-4055-b56a-2bb2b9c4d6ce
Kutz, Alexander
10599b2d-2007-4220-ba9f-df3454e4d945
Haubitz, Sebastian
de2ef4ab-0ebd-449f-a00a-dcf92ba3585f
Conen, Anna
d64e79b0-0197-4c9b-8cd1-013b6b424f9c
Bernasconi, Luca
d8a4e258-3e9a-45b0-bff3-dd4e7aba0840
Hammerer-Lercher, Angelika
8b288d65-9379-4550-8a52-8809ef29722d
Saeed, Kordo
87cb67e5-71e8-4759-bf23-2ea00ebd8b39
Mueller, Beat
50ac3513-fa7c-43eb-af01-4d8beb37c131
Schuetz, Philipp
ad48627c-d757-419c-bda1-a44b620bdd25
Gregoriano, Claudia
bf93f5bd-6dff-4906-8b2f-8751d03bb237
Koch, Daniel
476659ae-269d-4055-b56a-2bb2b9c4d6ce
Kutz, Alexander
10599b2d-2007-4220-ba9f-df3454e4d945
Haubitz, Sebastian
de2ef4ab-0ebd-449f-a00a-dcf92ba3585f
Conen, Anna
d64e79b0-0197-4c9b-8cd1-013b6b424f9c
Bernasconi, Luca
d8a4e258-3e9a-45b0-bff3-dd4e7aba0840
Hammerer-Lercher, Angelika
8b288d65-9379-4550-8a52-8809ef29722d
Saeed, Kordo
87cb67e5-71e8-4759-bf23-2ea00ebd8b39
Mueller, Beat
50ac3513-fa7c-43eb-af01-4d8beb37c131
Schuetz, Philipp
ad48627c-d757-419c-bda1-a44b620bdd25

Gregoriano, Claudia, Koch, Daniel, Kutz, Alexander, Haubitz, Sebastian, Conen, Anna, Bernasconi, Luca, Hammerer-Lercher, Angelika, Saeed, Kordo, Mueller, Beat and Schuetz, Philipp (2021) The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study. Clinical Chemistry and Laboratory Medicine, 59 (5), 995-1004. (doi:10.1515/cclm-2020-1295).

Record type: Article

Abstract

Objectives: midregional pro-adrenomedullin (MR-proADM) is a vasoactive peptide with key roles in reducing vascular hyperpermeability and thereby improving endothelial stability during infection. While MR-proADM is useful for risk stratification in patients with sepsis, clinical data about prediction accuracy in patients with severe acute respiratory syndrome coronavirus 2 disease (COVID-19) is currently missing.

Methods: we included consecutively adult patients hospitalized for confirmed COVID-19 at a tertiary care center in Switzerland between February and April 2020. We investigated the association of MR-proADM levels with in-hospital mortality in logistic regression and discrimination analyses.

Results: of 89 included COVID-19 patients, 19% (n=17) died while in the hospital. Median admission MR-proADM levels (nmol/L) were increased almost 1.5-fold increased in non-survivors compared to survivors (1.3 [interquartile range IQR 1.1-2.3]) vs. 0.8 [IQR 0.7-1.1]) and showed good discrimination (area under the curve 0.78). An increase of 1 nmol/L of admission MR-proADM was independently associated with a more than fivefold increase in in-hospital mortality (adjusted odds ratio of 5.5, 95% confidence interval 1.4-21.4, p=0.015). An admission MR-proADM threshold of 0.93 nmol/L showed the best prognostic accuracy for in-hospital mortality with a sensitivity of 93%, a specificity of 60% and a negative predictive value of 97%. Kinetics of follow-up MR-proADM provided further prognostic information for in-hospital treatment.

Conclusions: increased levels of MR-proADM on admission and during hospital stay were independently associated with in-hospital mortality and may allow a better risk stratification, and particularly rule-out of fatal outcome, in COVID-19 patients.

Text
10.1515_cclm-2020-1295 - Version of Record
Available under License Other.
Download (651kB)

More information

Accepted/In Press date: 15 December 2020
e-pub ahead of print date: 8 January 2021
Published date: 27 April 2021
Additional Information: Funding Information: Research funding: Costs for biomarker measurement (reagents) were externally sponsored by ThermoFisher Scientific, BRAHMS, Henningsdorf (Germany). This study was funded by Research Council KSA (Kantonsspital Aarau). The funding agency have no bearing on the study design, data collection and analysis or writing of the manuscript.
Keywords: biomarker, COVID-19, in-hospital mortality, prognostic markers, SARS-CoV-2

Identifiers

Local EPrints ID: 485387
URI: http://eprints.soton.ac.uk/id/eprint/485387
ISSN: 1434-6621
PURE UUID: fe3b3b14-5b45-4e56-adbf-ca2f1b15c582
ORCID for Kordo Saeed: ORCID iD orcid.org/0000-0003-0123-0302

Catalogue record

Date deposited: 05 Dec 2023 17:46
Last modified: 18 Mar 2024 03:52

Export record

Altmetrics

Contributors

Author: Claudia Gregoriano
Author: Daniel Koch
Author: Alexander Kutz
Author: Sebastian Haubitz
Author: Anna Conen
Author: Luca Bernasconi
Author: Angelika Hammerer-Lercher
Author: Kordo Saeed ORCID iD
Author: Beat Mueller
Author: Philipp Schuetz

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×